Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.
Longworth L, Yang Y, Young T, Mulhern B, Hernández Alava M, Mukuria C, Rowen D, Tosh J, Tsuchiya A, Evans P, Devianee Keetharuth A, Brazier J. Longworth L, et al. Among authors: tosh j. Health Technol Assess. 2014 Feb;18(9):1-224. doi: 10.3310/hta18090. Health Technol Assess. 2014. PMID: 24524660 Free PMC article. Review.
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A. Stevenson M, et al. Among authors: tosh j. Health Technol Assess. 2016 Apr;20(35):1-610. doi: 10.3310/hta20350. Health Technol Assess. 2016. PMID: 27140438 Free PMC article. Review.
Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A. Stevenson M, et al. Among authors: tosh j. Health Technol Assess. 2016 Nov;20(35):611-614. doi: 10.3310/hta20350-c201611. Health Technol Assess. 2016. PMID: 27919316 Free article. No abstract available.
The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.
Stevenson MD, Wailoo AJ, Tosh JC, Hernandez-Alava M, Gibson LA, Stevens JW, Archer RJ, Simpson EL, Hock ES, Young A, Scott DL. Stevenson MD, et al. Among authors: tosh jc. J Rheumatol. 2017 Jul;44(7):973-980. doi: 10.3899/jrheum.160941. Epub 2017 Feb 15. J Rheumatol. 2017. PMID: 28202743 Free article. Review.
67 results